Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Inhibikase Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Inhibikase Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| RA Capital Healthcare Fund LP | 10% Owner | 6,970,000Indirect | Jul 31, 2026 | 1 |
| Ra Capital Management, L.P. | 10% Owner | 6,970,000Indirect | Jul 31, 2026 | 1 |
| Kolchinsky Peter | 10% Owner | 6,970,000Indirect | Jul 31, 2026 | 1 |
| Shah Rajeev M. | 10% Owner | 6,970,000Indirect | Jul 31, 2026 | 1 |
| Berman Dennis N | Director | 21,854 | Jul 31, 2026 | 2 |
| Munshi Amit | Director | 38,176 | Jun 30, 2026 | 2 |
| Aurentz Vincent | Director | 510,596 | Jun 30, 2026 | 2 |
| Bellini Roberto | Director | 1,460,000Indirect | Jun 30, 2026 | 1 |
| Kush Arvind | Director | 145,000 | Jun 30, 2026 | 1 |
| Canner David | Director | – | Jun 30, 2026 | 1 |
| Cabell Christopher | President & Head of R&D | 676,564 | Feb 24, 2026 | 2 |
| McIntyre David | Chief Financial Officer | – | Jan 7, 2026 | 1 |
| Iwicki Mark T | Chief Executive Officer | – | Jan 7, 2026 | 1 |
| Sands Capital Alternatives, LLC | 10% Owner | 13,018,965 | Nov 24, 2025 | 1 |
| Sands Frank M. | 10% Owner | 13,018,965 | Nov 24, 2025 | 1 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 10% Owner | 13,018,965 | Nov 24, 2025 | 1 |
| Freeman Roy Lester | Director | – | Feb 19, 2025 | 0 |
| Werner Milton H. | President and CEO | 5,335,433 | Jan 22, 2025 | 0 |
| Lees-Rolfe Garth | Chief Financial Officer | – | Jan 22, 2025 | 0 |
| Grint Paul C | Director | – | Jul 18, 2024 | 0 |
| Dion Gisele | Director | – | Jul 18, 2024 | 0 |
| Frattaroli Joseph | Cheif Financial Officer | 48,091 | Mar 3, 2023 | 0 |
| O'Farrell Elizabeth G. | Director | – | Jun 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 (view filing)3:47 PM ET | Nov 21 | 3 days | Sands Capital Alternatives, LLC and 2 others10% Owner | PPurchase | +2.07M | $1.45 | +$3.00M | +18.9%13.0M after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Bellini RobertoDirector | PPurchase | +1.46M | $1.37 | +$2.00M | New position1.46M after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Kush ArvindDirector | PPurchase | +145.0K | $1.37 | +$198.7K | New position145.0K after | |
| Oct 23, 2024 (view filing) | Oct 21 | 2 days | Munshi AmitDirector | PPurchase | +365.0K | $1.37 | +$500.1K | New position365.0K after | |
| Aug 16, 2022 (view filing) | Aug 16 | Same day | Werner Milton H.President and CEO | PPurchase | +5.00K | $0.80 | +$4.00K | +0.1%5.34M after | |
| May 31, 2022 (view filing) | May 27 | 4 days | Werner Milton H.President and CEO | PPurchase | +5.00K | $0.98 | +$4.90K | +0.1%5.33M after | |
| May 23, 2022 (view filing) | May 20 | 3 days | Werner Milton H.President and CEO | PPurchase | +10.0K | $0.60 | +$6.00K | +0.2%5.33M after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Frattaroli JosephChief Financial Officer | PPurchase | +3.95K | $0.64 | +$2.53K | +8.9%48.1K after | |
| Nov 19, 2021 (view filing) | Nov 17 | 2 days | Werner Milton H.President and CEO | PPurchase | +23.6K | $1.97 | +$46.6K | New position23.6K after | 5 lots |